321 related articles for article (PubMed ID: 25482744)
1. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Blyth CC; Gilroy NM; Guy SD; Chambers ST; Cheong EY; Gottlieb T; McGuinness SL; Thursky KA
Intern Med J; 2014 Dec; 44(12b):1333-49. PubMed ID: 25482744
[TBL] [Abstract][Full Text] [Related]
2. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Fleming S; Yannakou CK; Haeusler GM; Clark J; Grigg A; Heath CH; Bajel A; van Hal SJ; Chen SC; Milliken ST; Morrissey CO; Tam CS; Szer J; Weinkove R; Slavin MA
Intern Med J; 2014 Dec; 44(12b):1283-97. PubMed ID: 25482741
[TBL] [Abstract][Full Text] [Related]
3. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.
van Hal SJ; Gilroy NM; Morrissey CO; Worth LJ; Szer J; Tam CS; Chen SC; Thursky KA; Slavin MA
Intern Med J; 2014 Dec; 44(12b):1277-82. PubMed ID: 25482740
[TBL] [Abstract][Full Text] [Related]
4. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014.
Morrissey CO; Gilroy NM; Macesic N; Walker P; Ananda-Rajah M; May M; Heath CH; Grigg A; Bardy PG; Kwan J; Kirsa SW; Slavin M; Gottlieb T; Chen S
Intern Med J; 2014 Dec; 44(12b):1298-314. PubMed ID: 25482742
[TBL] [Abstract][Full Text] [Related]
5. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.
Chen SC; Sorrell TC; Chang CC; Paige EK; Bryant PA; Slavin MA
Intern Med J; 2014 Dec; 44(12b):1315-32. PubMed ID: 25482743
[TBL] [Abstract][Full Text] [Related]
6. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
Rogers TR; Slavin MA; Donnelly JP
Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
[TBL] [Abstract][Full Text] [Related]
7. Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment.
Caira M; Trecarichi EM; Mancinelli M; Leone G; Pagano L
Expert Rev Anti Infect Ther; 2011 Jul; 9(7):881-92. PubMed ID: 21810058
[TBL] [Abstract][Full Text] [Related]
8. Changes in the epidemiological landscape of invasive mould infections and disease.
Lass-Flörl C; Cuenca-Estrella M
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009).
Klingspor L; Saaedi B; Ljungman P; Szakos A
Mycoses; 2015 Aug; 58(8):470-7. PubMed ID: 26152371
[TBL] [Abstract][Full Text] [Related]
10. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).
Lortholary O; Fernández-Ruiz M; Perfect JR
J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667
[TBL] [Abstract][Full Text] [Related]
11. [Invasive mould disease in haematological patients].
Ruiz-Camps I; Jarque I
Rev Iberoam Micol; 2014; 31(4):249-54. PubMed ID: 25434346
[TBL] [Abstract][Full Text] [Related]
12. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects.
Akan H; Antia VP; Kouba M; Sinkó J; Tănase AD; Vrhovac R; Herbrecht R
J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii5-16. PubMed ID: 24155144
[TBL] [Abstract][Full Text] [Related]
13. Changing patterns and trends in systemic fungal infections.
Richardson MD
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i5-i11. PubMed ID: 16120635
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
15. Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.
Lee CH; Lin C; Ho CL; Lin JC
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866872
[TBL] [Abstract][Full Text] [Related]
16. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.
Tragiannidis A; Dokos C; Lehrnbecher T; Groll AH
Drugs; 2012 Mar; 72(5):685-704. PubMed ID: 22413762
[TBL] [Abstract][Full Text] [Related]
17. [Prophylaxis of fungal infections in haematological patients: pro].
Glass B
Dtsch Med Wochenschr; 2010 Sep; 135(38):1870. PubMed ID: 20842607
[No Abstract] [Full Text] [Related]
18. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.
Chau MM; Kong DC; van Hal SJ; Urbancic K; Trubiano JA; Cassumbhoy M; Wilkes J; Cooper CM; Roberts JA; Marriott DJ; Worth LJ
Intern Med J; 2014 Dec; 44(12b):1364-88. PubMed ID: 25482746
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.
Douglas AP; Slavin MA
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1165-1177. PubMed ID: 27710140
[TBL] [Abstract][Full Text] [Related]
20. Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis.
Reslan Z; Lindsay J; Kerridge I; Gellatly R
Int J Clin Pharm; 2020 Dec; 42(6):1412-1418. PubMed ID: 33009604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
